

## Clark & Elbing LLP

101 Federal Street  
Boston, MA 02110

Telephone 617-428-0200  
Facsimile 617-428-7045  
617-428-7046

RECEIVED  
CENTRAL FAX CENTER

OCT 12 2005

**Date:** October 12, 2005

**To:** Examiner Teller  
U.S. Patent and Trademark Office  
Group Art Unit 1654

**Facsimile No.:** 571-273-8300

**From:** Kristina Bieker-Brady, Ph.D.  
Reg. No. 39,109

**Re:** U.S. Patent Application Serial No. 10/772,774  
NOVEL ANTIARRHYTHMIC PEPTIDES  
Larsen et al.  
Filed: February 4, 2004  
Attorney Docket No.: 50412/018003  
Customer No. 21559

**Pages:** 3, including cover page.

**Message:** The following papers are enclosed:  
Revocation and New Power of Attorney (2 pages)

NOTICE: This facsimile transmission may contain confidential or privileged information intended for the addressee only. If you are not the addressee, be aware that any disclosure, copying, distribution, or use of the information is prohibited. If you have received this facsimile transmission in error, please call us at 617-428-0200 to arrange for its return at no cost to you.

**BEST AVAILABLE COPY**

RECEIVED  
CENTRAL FAX CENTER

OCT 12 2005

PATENT  
ATTORNEY DOCKET NO. 50412/018003

Certificate of Facsimile Transmission: Date of Transmission: 10-12-05

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being transmitted by facsimile to the  
Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450;  
Facsimile No. 571-273-8300.

JANET D'ANNUNZIO-ELLIS  
Printed Name of Person Faxing Transmission

*Janet D'Annunzio-Ellis*  
Signature of Person Faxing Transmission

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Bjarne Due Larsen Art Unit: 1654  
Serial No.: 10/772,774 Examiner: Teller  
Filed: February 4, 2004 Customer No.: 21559  
Title: NOVEL ANTIARRHYTHMIC PEPTIDES

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

REVOCATION AND NEW POWER OF ATTORNEY

Under 37 C.F.R. § 3.73(b), Zealand Pharma A/S, a corporation, certifies that it is the  
assignee of 100% of the right, title, and interest in the patent application identified above by  
virtue of:

A chain of title from the inventors of the parent application, U.S. Serial No. 09/792,286,  
to the current assignee as shown below. Copies of the assignments or other documents in the  
chain of title are enclosed.

1. From Inventors Bjarne Due Larsen, Jorgen Soberg Petersen, Eddi Moier,  
Anne Louise Kjolbye, Niklas Rye Jorgensen, Morten Schak Nielsen,  
James B. Martins, and Niels-Henrik Holstein-Rathlou, to Zealand  
Pharmaceuticals A/S, as recorded in the Patent and Trademark Office at  
Reel 011864, Frame 0827, on June 6, 2001.
2. From Zealand Pharmaceuticals A/S to Zealand Pharma A/S, by a Change

BEST AVAILABLE COPY

of Name Certificate, as recorded in the Patent and Trademark Office at  
Reel 013152, Frame 0784, on August 5, 2002.

3. David Knott to Zealand Pharma A/S, as recorded in the Patent and  
Trademark Office at Reel 015142, Frame 0709, on March 29, 2004.

The present application is a continuation of U.S. Serial No. 09/792,286, and thereby this  
assignment is applied to the present application (M.P.E.P. §306).


The undersigned, acting on behalf of the assignee, hereby revokes all powers of attorney  
previously granted in the application and appoints the attorneys and/or agents of Clark & Elbing  
LLP, associated with customer number 21559, with full power of substitution and revocation, to  
prosecute the application and to transact all business in the United States Patent and Trademark  
Office connected therewith.

All correspondence regarding the application should be sent to the address associated  
with customer number 21559.

I hereby declare that all statements made herein of my own knowledge are true and that  
all statements made on information and belief are believed to be true; and further that these  
statements were made with the knowledge that willful false statements and the like so made are  
punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States  
Code and that such willful false statements may jeopardize the validity of the application or any  
patents issued thereon.

Date: 11/10/05

Respectfully submitted,

  
Zealand Pharma A/S  
Eva Steinhilber  
COO

BEST AVAILABLE COPY